Cancer cells alter metabolic processes to sustain their characteristic uncontrolled growth
and proliferation. These metabolic alterations include (1) a shift from oxidative …

Cancer cells characterized by uncontrolled growth and proliferation require altered
metabolic processes to maintain this characteristic. Metabolic reprogramming is a process …

Despite the remarkable progress in cancer treatment up to now, we are still far from
conquering the disease. The most substantial change after the malignant transformation of …

Abstract Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated
metabolic genes across human cancers. These hotspot gain‐of‐function mutations cause …

Abstract Treatment of acute myeloid leukemia (AML) with chemotherapeutic agents fails to
eliminate leukemia stem cells (LSC), and thus patients remain at high risk for relapse …

High serum urate is a prerequisite for gout and associated with metabolic disease. Genome-
wide association studies (GWAS) have reported dozens of loci associated with serum urate …

Herein, we provide a brief overview of the synthesis and applications of
trifluoromethylpyridine (TFMP) and its derivatives in the agrochemical and pharmaceutical …

Cancer, responsible for approximately 10 million lives annually, urgently requires innovative
treatments, as well as solutions to mitigate the limitations of traditional chemotherapy, such …

New series of substituted 2-alkoxycyanopyridine derivatives were synthesized and
evaluated for their in vitro and in vivo anticancer activities. Comparing the evaluated …

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) interfere with cellular metabolism
contributing to oncogenesis. Mutations of IDH2 at R140 and R172 residues are observed in …